Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparison Between Monoclonal Antibody CD20 Treatment (Rituximab (mabthera))and General Corticotherapy Treatment in Patients With Pemphigus

Trial Profile

Comparison Between Monoclonal Antibody CD20 Treatment (Rituximab (mabthera))and General Corticotherapy Treatment in Patients With Pemphigus

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rituximab (Primary) ; Corticosteroids
  • Indications Pemphigus; Pemphigus vulgaris
  • Focus Registrational; Therapeutic Use
  • Acronyms Ritux 3; Rituximab 3
  • Most Recent Events

    • 18 Mar 2020 Results of a post-hoc analysis published in the JAMA Dermatology
    • 14 Dec 2019 Article focusing on the efficacy and safety/tolerability of rituximab in combination with a tapering course of corticosteroids in the treatment of adults with moderate to severe PV published in the American Journal of Clinical Dermatology
    • 05 Sep 2019 Results of post-hoc analysis published in the British Journal of Dermatology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top